Interleukin-28B Polymorphism is a Pharmacogenetic Predictor during Sofosbuvir Plus Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C Egyptian Patients

EL-Raheem, Hosni Dh Abd; Hashem, Medhat H.; Hemeida, Alaa A.; Ebeed, Mohamed E; Arafa, Usama Ahmed; Yousef, Laila M

doi:10.4172/2153-0645.1000166

Cited by 3 publications

(1 citation statement)

References 45 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data also indicate that, CC (major) genotype of IFNL3 (rs12979860) was identified in much higher frequency in SVR patients (39.5%) when compared with relapsers (10.5%), nonresponders (17%), and non‐SVR patients (13%), indicating the association of CC (major) genotype with the likelihood of achieving SVR in comparison with non‐CC variants. This finding was further supported by previous studies that the CC variant of rs12979860 was associated with an increased likelihood of achieving SVR in comparison with non‐CC variants . Asselah et al showed a better treatment response rate of the C Allele of the IFNL3 (rs12979860).…”

Section: Discussionsupporting

confidence: 72%

Polymorphism in interferon λ3/interleukin‐28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy

Khan

Saraswat

Ranjan

et al. 2018

Journal of Medical Virology

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a considerable public‐health problem and an important cause of liver disease with about 71 million people infected worldwide and more than 399 000 people die every year from hepatitis C‐related liver diseases. The present study was, therefore, initiated to investigate the association of polymorphism in interferon λ3 (IFNL3) also known as interleukin‐28B (IL‐28B) gene with chronic HCV infection and association of these polymorphic variants with the combination daclatasvir and sofosbuvir HCV therapy response. Genotypes were determined by the polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP) assay in a total of 250 chronic HCV genotype three patients and 500 number of healthy controls. Our data revealed that the TT (minor) genotype of IFNL3 (rs12979860) and GG (minor) genotype of IFNL3 (rs8099917) exhibited a significant association with chronic HCV genotype 3 infection when compared with controls. The results of treatment response showed that CC (major) genotype of IFNL3 (rs12979860) and TT (major) genotype of IFNL3 (rs8099917) are associated with the likelihood of achieving a higher sustained virological response (SVR), to combined daclatasvir and sofosbuvir therapy, in genotype 3‐infected HCV patients, whereas the individuals with TT (minor) genotype of IFNL3 (rs12979860) and GG (minor) genotype of IFNL3 (rs8099917) are more susceptible to chronic HCV infection and treatment relapse, suggesting a role of IFNL3 (rs12979860) and (rs8099917) in the treatment outcome of combined daclatasvir and sofosbuvir therapy in chronic HCV genotype 3 infection.

show abstract

Section: Discussionsupporting

confidence: 72%

Polymorphism in interferon λ3/interleukin‐28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy

Khan

Saraswat

Ranjan

et al. 2018

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

Interleukin 28B Polymorphism as a Predictor of Response to Treatment of Egyptian HCV Patients Working in Nuclear Material Authority

Zidan

Talaat

Ammar

et al. 2019

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Predictive Value of IL-28B rs12979860 Variants for Peg-IFN, Sofosbuvir Plus Ribavirin Treatment of HCV Infection in Pakistani Population

et al. 2018

View full text Add to dashboard Cite

Aim: The correlation of IL28-B genetic variants (rs12979860) with combinational therapy (peg-interferon, sofosbuvir plus ribavirin) of hepatitis C virus infection were studied in 154 chronic hepatitis C patients. Methods & results: The sustained virological response for efficient antiviral regimen was achieved in 75.32% treated individuals. Three genotypes of rs12979860 (CC, CT and TT) were compared both in sustained virological response and nonresponders groups (p = 0.25, p ≤ 0.001, p = 0.10, respectively). CT genotype demonstrated a significant correlation (p ≤ 0.001) in both groups with higher positive predictive value (81.55%). Conclusion: IL28 polymorphism and positive predictive value may be considered as the markers for the evaluation of the effectiveness of the treatment regimen. Further clinical trials are recommended to verify the role of IL28-B in hepatitis C virus treatment.

show abstract

Interleukin-28B Polymorphism is a Pharmacogenetic Predictor during Sofosbuvir Plus Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C Egyptian Patients

Cited by 3 publications

References 45 publications

Polymorphism in interferon λ3/interleukin‐28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy

Polymorphism in interferon λ3/interleukin‐28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy

Interleukin 28B Polymorphism as a Predictor of Response to Treatment of Egyptian HCV Patients Working in Nuclear Material Authority

Predictive Value of IL-28B rs12979860 Variants for Peg-IFN, Sofosbuvir Plus Ribavirin Treatment of HCV Infection in Pakistani Population

Contact Info

Product

Resources

About